From owner-freebsd-ia64 Mon Jan 7 10: 2: 2 2002 Delivered-To: freebsd-ia64@freebsd.org Received: from freefall.freebsd.org (freefall.FreeBSD.org [216.136.204.21]) by hub.freebsd.org (Postfix) with ESMTP id 8259337B41D for ; Mon, 7 Jan 2002 10:00:20 -0800 (PST) Received: (from fenner@localhost) by freefall.freebsd.org (8.11.6/8.11.6) id g07I08x05994 for freebsd-ia64@freebsd.org; Mon, 7 Jan 2002 10:00:08 -0800 (PST) (envelope-from fenner) Date: Mon, 7 Jan 2002 10:00:08 -0800 (PST) From: Message-Id: <200201071800.g07I08x05994@freefall.freebsd.org> To: freebsd-ia64@freebsd.org Subject: FreeBSD ports: 1 unfetchable distfiles: emulators/ski Sender: owner-freebsd-ia64@FreeBSD.ORG Precedence: bulk List-ID: List-Archive: (Web Archive) List-Help: (List Instructions) List-Subscribe: List-Unsubscribe: X-Loop: FreeBSD.org Dear freebsd-ia64@freebsd.org, You are listed as the FreeBSD port maintainer for 1 port whose distfiles [or main web pages] are not fetchable from their MASTER_SITES. Could you please visit http://people.freebsd.org/~fenner/portsurvey/freebsd-ia64@freebsd.org.html and correct the problems listed there? The individual port with a problem is emulators/ski. Note that the main port web page, as listed in the WWW: line of the pkg-descr, is checked just as though it was a port distfile. This is an unfortunate side effect of the architecture of the distfile survey reporting system, but if you see a distfile being reported as not fetchable that's not actually a distfile, see if it's from the pkg-descr. If you have already corrected the problems and submitted a PR, please accept my thanks and apologies for the delay in getting the fixes into the tree. This reminder is created automatically and does not (yet) have a way to know if a PR fixing the problem has been submitted. Please do *NOT* submit your response to me directly; I do not always have time to commit your fix; please instead submit a PR via 'send-pr' so it doesn't get lost. Problems are usually of two types: 1. The software package has been upgraded and the version in the port has been removed. The best solution to this problem is to upgrade the port to the most current version of the software package. If you are a FreeBSD committer, then you can just upgrade the port directly. If not, you should create the new port on your own system, test it (and maybe even run "portlint" on it), and then use "send-pr" to submit a "diff -uNr old-port new-port". If you added or deleted any files, please make an explicit note of it. 2. The mirror site being used no longer contains the software package in question, or no longer exists. Solutions include: a) If there are other mirror sites, just remove the bad site from the list. (Make sure that what appears to be a bad site isn't actually a problem of type 1, upgrade) b) If the README or other support files in the software documentation mention where to get the software package, use one of those sites. c) Use ftpsearch (http://ftpsearch.ntnu.no/ftpsearch) or other search engines to find another place to get the original DISTFILES. Make sure that you don't pick a FreeBSD distfiles mirror -- if you can't find any other places where the file exists, it can be a LOCAL_PORT or you can simply comment out the MASTER_SITES= line, with a comment explaining why. Once you have a solution, use "send-pr" to submit a "diff -u" of the Makefile. Note that this isn't an urgent issue, as people who try to build the port now will just fall back to the FreeBSD distfiles mirror. Please just put it on your list to do and get to it when you have time. These messages will continue to arrive twice a month until the fix is committed, as a reminder. Thanks, Bill "distfiles" Fenner. To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-ia64" in the body of the message From owner-freebsd-ia64 Fri Jan 11 3:57:55 2002 Delivered-To: freebsd-ia64@freebsd.org Received: from pios.library.ohyama.toyama.jp (pios.library.ohyama.toyama.jp [61.127.24.243]) by hub.freebsd.org (Postfix) with ESMTP id 928E337B42B; Fri, 11 Jan 2002 03:51:42 -0800 (PST) Received: from mx2.eudoramail.com ([207.93.225.196]) by pios.library.ohyama.toyama.jp (Build 101 8.9.3/3.5Wpl7-pios) with ESMTP id UAA28006; Fri, 11 Jan 2002 20:48:16 +0900 From: WSCHwatch@eudoramail.com Message-ID: <0000723b1f00$00005805$00006b6e@mx2.eudoramail.com> To: Subject: WSCH: Baby Pharmaceutical on the Rise T Date: Fri, 11 Jan 2002 05:45:46 -1800 MIME-Version: 1.0 Content-Type: text/html; charset="iso-8859-1" Content-Transfer-Encoding: quoted-printable Reply-To: WSCHnews25@eudoramail.com Sender: owner-freebsd-ia64@FreeBSD.ORG Precedence: bulk List-ID: List-Archive: (Web Archive) List-Help: (List Instructions) List-Subscribe: List-Unsubscribe: X-Loop: FreeBSD.org = Investors
<= td width=3D100% height=3D372 valign=3Dtop align=3Dleft>
  &n= bsp;   Key Points about = WSCH:
  • The products and me= dical therapies developed by WSCH represent possibly the most important= breakthrough in the field of Dermatology in the last fifty years.&nbs= p;

  • WSCH anticipates= FDA approval on seven over-the-counter products within the next ye= ar, which will provide significant revenue in the retail drug market.
    =
  • WSCH has experie= nced a success rate of 90% during clinical studies, completely elim= inating skin disease from 90% of all patients treated.

  • By year five, WSCH plans to have annua= lized revenue over $525 million and over $125 million in EBIT.  This does not take into account income from OTC products which wi= ll be substantial.

 <= /caption>
=

Emergin= g Growth Stock Alert
Wasatch Pharmaceuticals: A Company on the Rise

Company Name &n= bsp;Wasatch Pharmaceuticals (OTCBB: WSCH)
Current = Price$0.066
52-We= ek High$27.50
5= 2-Week Low$0.065
<= /div>

Company Background

Wasatch Pharmaceutical, Inc. is a fourteen year o= ld company with a record of outstanding achievements in the field of Derma= tology.  Under the name of its subsidiary, American Institute of Skin= Care (AISC), Wasatch has operated two prototype clinics for the la= st five years where the products and medical therapies have been tested an= d proven on hundreds of patients.  The Company's activities have been= centered on research in the area of serious skin diseases.  A= concurrent discovery and benefit is WSCH's dramatic success in the area o= f skin rejuvenation.  Seeing the high growth potential from major fun= ding, WSCH elected to become a public company less than two years a= go.

Wasatch's major successes i= n the area of skin diseases include: 

Cystic Acne, Eczema= , Seborrhea, Contact Dermatitis, Molluscum, Folliculitis, Acne Rosacea and= less prevalent skin diseases.  

Interestingly, the= se skin disorders account for more than 70% of all business in the = field of dermatology for which there are very few (if any) safe, effective= therapies like those developed by Wasatch.

Because the th= erapies developed by Wasatch dominate this area of medicine, WSCH h= as elected to market its products via company-owned clinics throughout the= United States.  This decision has resulted in the establishment of <= b>two research clinics in Utah for the purpose of implementing procedu= res within the clinics pursuant to testing and confirming the results that= were achieved in past clinical trials.  Due to its success rate o= f 90% on hundreds of patients over a five year period, WSCH's clinics = are now on line with insurance providers independent of HMOs.  Effort= s to establish Preferred Provider ship status with HMOs are presently bein= g pursued. 

Most Recent WSCH News

 

Wasatch Pharmaceutical Inc. Announc= es a New Physician Marketing Campaign and Listing On German Stock Exchange= s

MURRAY, Utah--(BUSINESS WIRE)--Nov.= 27, 2001--Wasatch Pharmaceutical Inc. (OTCBB:WSCH - news) CEO Gary Heesch announced today a marketing camp= aign directed to physicians. A direct link has been established on a physi= cian recruiting Web site making available therapies for the treatment of c= ystic acne, acne, folliculitis, and skin rejuvenation. Physicians will fin= d the benefits of these treatment therapies by logging on to the "= X Acne" link at physicianssearc= h.com. This physician search Web site typically receives over 2= 00,000 hits per month. Mr. Heesch reminded, "Our treatment therap= y products are also available via the AISC Online Store at restoremyskin.com.'"

These skin treatment products come in kit form providing a = 90-day supply to patients for the full treatment program. Included in the = kit is an instructional video on the treatment therapy allowing the patien= t to use these products in their home. The therapies, when used as instruc= ted, achieve a success rate of eradication in excess of 90% with no sid= e effects of any consequence. Previously, these therapies and associat= ed products were only available through the two prototype clinics in Utah.= The availability of these products will open the way for family practitio= ners, pediatricians, internists and other primary care physicians to retai= n their patients under their care during the treatment of these common ski= n disorders. The benefit to insurance providers is the potential to sav= e millions of dollars in reimbursement costs by freeing the physician and = the patient from ongoing treatment.

In the coming year, six additional therapies will be made availabl= e for a broad range of skin disorders that are badly in need of succes= sful therapies.

Gary Heesch also an= nounced the listing of Wasatch Pharmaceutical stock on the Frankfurt an= d Berlin Exchanges in Germany. Active trading on these exchanges will = take place upon the completion of a research report in Germany. Said Mr. H= eesch, "We feel this is a significant event as Wasatch will gain w= ider exposure as a leader in dermatology and will put buying pressure on its stock to reflect the true value of a company t= hat has committed years of research and development of products that allow= people with serious skin disorders to live normal and more productive liv= es."

There may be forward-loo= king statements in this release. Investors are cautioned that such forward= -looking statements involve risks and uncertainties, including, without li= mitation, continued acceptance of the Company's products, increased levels= of competition, new products introduced by competitors, changes in the ra= tes of subscriber acquisition and retention, and other risks detailed from= time to time in the Company's periodic reports filed with the Securities = and Exchange Commission.

Projections, Objectives, and Statistics

 Over a five year period, AISC (WSCH's subsidiary) p= lans to establish 350 clinics in over 100 major population areas.&n= bsp; The company plans to hire over 150 medical doctors for these clinics,= train over 1,000 medical assistants and treat over 2,000,000 patients<= /b>. Also by year five, WSCH plans to have annualized over $525 million= in revenue and over $125 million in EBIT. This does not take into acc= ount income from OTC products which will be substantial. 

<= blockquote>

  As of 1991, there were = approximately 14 million chronic acne and eczema patients annually in the = United States, with the highest percentage between 18 to 44 years of = age. The actual number of patients with any type of acne is significa= ntly higher.  Seven billion dollars is spent annually on derma= tological pharmaceutical products for these disorders. 

=   In 1994, the teen population reached 25 million. During the next d= ecade, it will grow at nearly twice the rate of 
the overall p= opulation (according to U.S. Census Bureau projections). Acne pat= ients are primarily teenagers, whereas eczema patients range from inf= ants to the elderly.

A Look at the Competition

= Dermatologists are the primary competitors of WSCH's clinics. Dermatologis= ts specialize in the treatment of skin disorders and prescribe medications= to treat the disorder.  However, competing products address the s= ymptoms of acne and eczema, not the cause. 

<= font face=3DVerdana size=3D2>The competition's skin care treatments includ= e prescription medications (oral and external use drugs prescribed by derm= atologists and other doctors) and over-the-counter products.  
Several common prescription medications include: 
= 1) E-Mycin for oral and topical use, 2) Cleocin for oral and topical use, = 3) Tetracycline for oral and topical use, and 4) Accutane for oral use onl= y.  

Over-the-counter acne medications include: = ;
1) Clearasil and Oxy creams, 2) generic brand creams, 3) medicat= ed pads, and 4) medicated soaps. 

Many of the competit= ion's oral medications have serious side effects.

Costs for competing treatments range from $2.50 for= medicated soaps to $200 for Accutane oral medication prescription.  = Treatments are on-going.  Over time a person can spend an unlimite= d amount of money on such treatments.  An example would be someon= e who spent $1,500 for a 22 week program of Accutane which includes blood = testing.  Another example would be someone who has had acne for many = years and has spent in excess of $34,000. 

At this time there is no known competitor who treats t= he causes of these skin disorders and no competitor can claim a success= rate equal to that of Wasatch's treatments. 

Final Thoughts on WSCH<= /b>

Wi= th a proven success rate of 90% in a field that affects so many of our liv= es, Wasatch has clearly positioned itself in a market hungry and desper= ate for successful products and treatment.  WSCH has recently exp= anded its marketing presence (as seen in the above press release) and will= continue to aggressively broaden awareness over the near term. The listin= g of WSCH on the German stock exchange is another sign of the compa= ny's credibility and ambitious plans to establish itself as a major glo= bal player in the field of dermatology.  

WSCH has = taken on a completely different approach.  By addressing the causes o= f skin disorders rather than the symptoms, WSCH will help to successfully = eliminate skin disease altogether. Given its 

1. Successful = 14-year history and plans for expansion
2. Impressive revenue projecti= ons ($525 million+ annualized by year 5 and $125 million in EBIT)
= 3. Virtually unmatched success rate of 90%...

...and so much = more, WSCH will certainly watched by savvy investors for some time to come= .

DISCLAIMER= : 
Information within this email contains "forward looking s= tatements" within the meaning of Section 27A of the Securities Act of= 1933 and Section 21B of the Securities Exchange Act of 1934. Any statemen= ts that express or involve discussions with respect to predictions, expect= ations, beliefs, plans, projections, objectives, goals, assumptions or fut= ure events or performance are not statements of historical fact and may be= "forward looking statements."

Forward looking statemen= ts are based on expectations, estimates and projections at the time the st= atements are made that involve a number of risks and uncertainties wh= ich could cause actual results or events to differ materially from those p= resently anticipated. Forward looking statements in this action may be ide= ntified through the use of words such as "projects", "fores= ee", "expects", "will,"  "anticipates," "estimates," "believes," "understands" o= r that by statements indicating certain actions "may,"= ; "could," or <= font face=3DVerdana size=3D1 color=3D#5F5F5F>"might" = occur.  All information provided within this email pertaining to inve= sting, stocks, securities must be understood as information provided and n= ot investment advice. Emerging Growth Stock Alert advises all readers and = subscribers to seek advice from a registered professional securities = representative before deciding to trade in stocks featured within this ema= il.  None of the material within this report shall be construed as an= y kind of investment advice.

In compliance with the Securities Ac= t of 1933, Section17(b), Emerging Growth Stock Alert discloses the receipt= of $40,000 cash from a third party for the publication of this report and= additional services related= to WSCH. Be aware of an inherent conflict of interest resulting from such= compensation.  All factual information in this report was gathe= red from public sources, including but not limited to SEC filings, Company= Press Releases, and the company's website at wasatchpharm.com. Emerging Growth Stock Alert believes t= his information to be reliable but can make no guarantee as to its accurac= y or completeness. Use of the material within this email constitutes your = acceptance of these terms.



To b= e removed from future mailings, please respond
to this email with &qu= ot;Remove" in the subject line

<= /div> To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-ia64" in the body of the message From owner-freebsd-ia64 Sat Jan 12 0:59:14 2002 Delivered-To: freebsd-ia64@freebsd.org Received: from mel-rto1.wanadoo.fr (smtp-out-1.wanadoo.fr [193.252.19.188]) by hub.freebsd.org (Postfix) with ESMTP id 06EE537B417 for ; Sat, 12 Jan 2002 00:59:12 -0800 (PST) Received: from mel-rta9.wanadoo.fr (193.252.19.69) by mel-rto1.wanadoo.fr; 12 Jan 2002 09:59:10 +0100 Received: from smtp.wanadoo.fr (80.13.121.214) by mel-rta9.wanadoo.fr; 12 Jan 2002 09:58:57 +0100 Message-Id: <1010826031.170@wanadoo.fr> Date: Sat, 12 Jan 2002 10:00:31 0100 To: ia64@FreeBSD.org From: opticia@hotmail.com (opticia) Subject: OPTIQUE ET LENTILLES DE CONTACT MIME-Version: 1.0 Content-Type: text/html; charset="iso-8859-1"; format=flowed Sender: owner-freebsd-ia64@FreeBSD.ORG Precedence: bulk List-ID: List-Archive: (Web Archive) List-Help: (List Instructions) List-Subscribe: List-Unsubscribe: X-Loop: FreeBSD.org LENTILLES DE CONTACT A PRIX COUTANT ! ! ! LENTILLES MENSUELLES : Acuvue 2 : 22,5 E (147.59 f) Surevue : 27 E (177.11 f) Soflens comfort : 23 E (150.87 f) LENTILLES JOURNALIERES : Focus dailies *30 : 20 E (131.19 f) Focus dailies *90 : 44 E (288.62 f) LENTILLES DE COULEURS : mauve, turquoise, bleu, gris, noisette, vert amande... avec ou sans correction Freshlook colorblends : 19 E (124.63 f) PRODUITS (PU*3) : Renu : 7.5 E (49.20 f) Optifree : 7.5 E (49.20 f) Complete : 10.5 E (68.88 f) Solocare : 9.5 E (62.32 f) Aosept : 11 E (72.16 f) Toutes autres marques disponibles Devis par téléphone ou par email Possibilité de vente par correspondance EN LUNETTERIE : Nouvelles collections 2002 Gucci, Chanel, Dior, Armani, Mikli, Starck, Matsuda, Rayban... JUSQU'AU 28/02/02 : Une monture et 2 verres correcteurs sont offerts pour tout achat d'un équipement optique. O P T I C I A 64 Rue de Vaugirard - 75006 Paris Tél : 01 42 22 11 15 Du Lundi au Samedi de 10h à 19h30 Pour ne plus recevoir d'email, envoyer un message vide à opticia@hotmail.com avec REMOVE comme sujet To Unsubscribe: send mail to majordomo@FreeBSD.org with "unsubscribe freebsd-ia64" in the body of the message